For many women in the UK, managing weight is not just about physical health—it also relates to reproductive wellbeing. With rising interest in Wegovy weight loss treatment, women of childbearing age are increasingly asking whether this GLP-1 medication has any bearing on fertility and pregnancy planning.This article explores the current understanding of Wegovy (semaglutide) in the context of fertility, how it interacts with the reproductive system, and what UK women need to know when considering pregnancy after or during treatment.What Is Wegovy and How Does It Work?Wegovy is a prescription medication designed for chronic weight management. It contains semaglutide, a GLP-1 receptor agonist originally developed to treat type 2 diabetes but now licensed for obesity treatment. It is administered as a Wegovy weekly injection, and works by mimicking GLP-1, a natural hormone that regulates appetite and food intake.Wegovy helps reduce hunger and promotes a sense of fullness, making it easier for individuals to reduce caloric intake and manage weight more effectively. It is typically prescribed to individuals with a body mass index (BMI) of 30 or higher, or 27 with obesity-related conditions.As a GLP-1 weight loss medication, Wegovyrepresents a modern approach to treating obesity, offering support where lifestyle changes alone have not yielded sufficient results.The Link Between Obesity, Weight Loss, and FertilityObesity can have a significant impact on fertility. In women, it is associated with hormonal imbalances, irregular menstrual cycles, and conditions like polycystic ovary syndrome (PCOS), all of which can reduce the chances of conception.Evidence shows that losing even a modest amount of weight—around 5% to 10% of body weight—can improve ovulation and restore more regular menstrual cycles. For this reason, many fertility specialists recommend weight loss as a first-line strategy for women struggling to conceive due to excess weight.In this context, Wegovy for obesity may serve as a clinical tool to help patients achieve weight loss goals that support reproductive health. However, the use of semaglutide around conception and during pregnancy must be approached with caution.Can Wegovy Directly Influence Fertility?The direct relationship between Wegovy and fertility is not fully understood, as clinical trials on this specific topic are limited. There is no confirmed evidence suggesting that Wegovy weight loss treatment enhances or harms fertility on its own.However, semaglutide for weight loss may help facilitate natural improvements in fertility by reducing body weight. As weight loss can restore ovulatory function, it’s possible that fertility may improve indirectly as a result ofWegovy’s action on weight regulation.Animal studies have shown some reproductive effects at high dosages of semaglutide, but these findings do not necessarily translate to humans. Given the limited data, it is recommended that women of reproductive age consult with their healthcare provider to weigh the benefits and potential risks.Wegovy Use and Pregnancy Planning: What’s the Guidance?For women planning to become pregnant, the UK’s current medical guidance is clear: Wegovy should not be used during pregnancy, and treatment should be discontinuedat least two months before trying to conceive.Semaglutide has a long half-life, meaning it stays in the body for several weeks after administration. Therefore, even if a patient stops using the Wegovy injection, the drug may still remain in their system for some time.This precautionary approach is based on limited human pregnancy data and the potential for unknown effects on fetal development. While Wegovy side effects such as nausea or gastrointestinal discomfort are common during treatment, the impact on pregnancy is not fully known, making preconception planning crucial.If you are considering pregnancy, speak to your GP or prescribing clinician about safely discontinuing the medication and ensuring your body is ready for conception.What About Fertility Treatments Like IVF?For women undergoing assisted reproductive techniques such as in vitro fertilisation (IVF), weight loss may be recommended to improve the likelihood of a successful outcome. Some fertility clinics set BMI thresholds before beginning treatment.In such cases, GLP-1 weight loss medications like Wegovy may assist with reaching a suitable BMI prior to treatment. However, it must be timed carefully. The two-month washout period before conception still applies, meaning semaglutide treatment must end well before ovulation induction or embryo transfer.The decision to include Wegovy as part of preconception weight management should be made collaboratively between a fertility specialist and the prescribing doctor.Supporting Fertility Through Lifestyle MeasuresRegardless of whether Wegovy is used, women planning a pregnancy are advised to prioritise healthy lifestyle habits to support fertility. This includes:
- Maintaining a balanced, nutrient-rich diet
- Exercising regularly
- Managing stress levels
- Tracking ovulation to identify fertile windows
- Ensuring appropriate supplementation (e.g., folic acid)
